Dysregulation of the complement system has been implicated in the pathogenesis of age-related macular degeneration. To investigate consequences of altered complement regulation in the eye with age, we examined Cd59a complement regulator deficient (Cd59a À/À ) mice between 4 and 15 months. In vivo imaging revealed an increased age-related accumulation of autofluorescent spots in Cd59a À/À mice, a feature that reflects accumulation of subretinal macrophages and/or microglia. Despite this activation of myeloid cells in the eye, Cd59a À/À mice showed normal retinal histology and function as well as normal choroidal microvasculature. With age, they revealed increased expression of activators of the alternative complement pathway (C3, Cfb, Cfd), in particular in the retinal pigment epithelium (RPE)-choroid but less in the retina. This molecular response was not altered by moderately-enhanced light exposure. Cd59a deficiency therefore leads to a preferential age-related dysregulation of the complement system in the RPE-choroid, that alone or in combination with light as a trigger, is not sufficient to cause choroidal vascular changes or retinal degeneration and dysfunction. This data emphasizes the particular vulnerability of the RPE-choroidal complex to dysregulation of the alternative complement pathway during aging.
Introduction
Data from immunohistochemical studies and genome-wide association studies have supported the hypothesis that dysregulation of the complement system plays a major role in the development of age-related macular degeneration (AMD), the most common cause of blindness in the western world (Lim et al., 2012) . Postmortem analysis have shown that complement factors and other proinflammatory substrates are a main component of drusen, the hallmark feature of AMD (Hageman et al., 2001) . Further support for an important role of the complement system in AMD came from the identification of several polymorphisms in genes of the complement pathway that modify disease risk (for a review on AMD, see Lim et al., 2012) . In particular, the alternative complement pathway seems to be involved with a polymorphism in the complement factor H (CFH)-gene (Y402H), harboring a major risk for the development of AMD (Klein et al., 2005) . The activation of the alternative complement pathway is not dependent on activation via antibody fragments or lectin but is instead the consequence of the balance between constant autoactivation and tight control through regulators of the complement system such as CFH, CD55, CFI, or CD59 (Lim et al., 2012; Zipfel and Skerka, 2009 ). Most complement proteins of the fluid phase are produced by the liver and distributed in the plasma, underlining the role of complement as a systemic player in immunology. However, more evidence is evolving that the local role, especially of long-term activation in organs with a distinct immunity and barriers such as brain and eye plays an important role. It is known that the retinal pigment epithelium (RPE) and neurosensory retina do express complement factors and that the expression increases with age Hageman et al., 2001; Luo et al., 2011) . In the last years, several clinical trials which aim to modify complement activation in the eye by intravitreal or systemic delivery of monoclonal antibodies have been launched Lim et al., 2012 ) that target, for example, the alternative complement pathway by inhibiting complement factor D (CFD) (Lampalizumab, Genentech, NCT01602120) or the activation of the terminal complement pathway by inhibiting C5 and interfering with membrane-attack complex formation similar to but upstream of CD59 (Eculizumab, Alexion Pharmaceuticals, NCT00935883) (Yehoshua et al., 2014) .
Aging, the biggest risk factor for AMD, causes structural changes which require adaptive responses of the tissue. These responses might lead to chronic low-level inflammation, and thus, further upregulation of local cytokine and complement gene or factor expression, increased macrophage accumulation, and structural changes of the extracellular matrix, a process often referred to as parainflammation that might also play an important role in the development of AMD (Hageman et al., 2001; Xu et al., 2009) . Why AMD, a slow disease that progresses over life time, is so strongly defined by polymorphisms in the innate immune system, a system that has been historically linked with a very fast and direct activation, and why those changes increase disease risk in the eye, remains currently unresolved but might be linked to the particular characteristics of the eye.
CD59, also called membrane inhibitor of reactive lysis or protectin, is a glycosylphosphatidylinositol (GPI) anchored membrane-bound protein (Kieffer et al., 1994 ) that protects host tissue by blocking the assembly of the membrane-attack complex through binding to C9, thus inhibiting its integration into the C5b-9 complex (Lachmann, 1991) . In human, it is widely expressed on cells of all tissues (Meri et al., 1991) . CD59 has been implicated in paroxysmal nocturnal hemoglobinuria, a rare clonal hematopoietic stem cell disorder that leads to complement-mediated lysis of erythrocytes and release of hemoglobin into the urine. Somatic mutations in the X-linked PIGA gene (Xp22.1) lead to an insufficient GPI synthesis and thus to an absence of GPI-anchored proteins such as decay-accelerating factor (CD55) and CD59 on the clonally-derived cells (Brodsky, 2006) . Interestingly, recent studies have also found a decreased local expression of CD59 in the RPE of AMD donor eyes compared with age-matched controls, suggesting a reduced local complement regulation at the level of the RPE in AMD (Ebrahimi et al., 2013) .
In mice, the small (20 kDa) Cd59 protein is expressed in 2 isoforms (Qian et al., 2000) . Although mouse Cd59a is known to be the human ortholog, Cd59b is predominantly expressed in testis and its knockout leads to increasing male infertility (Donev et al., 2008) . Cd59a is strongly expressed in the neurosensory retina and to a lesser extent in RPE (Faber et al., 2012) , and expression in the mouse eyecup is stronger than in nonocular tissue (Yang et al., 2009 ). In vitro experiments on primary human RPE cells showed expression of complement regulators such as CD59 and their upregulation as a response to inflammatory cytokines (Yang et al., 2009) .
To understand the function of CD59, knockout mice have been used in many disease models. Deficiency of Cd59a in mice has been shown to worsen experimental autoimmune myasthenia (Morgan et al., 2006) , Wallerian degeneration (Ramaglia et al., 2009) , neural tau pathology, and neural degeneration (Britschgi et al., 2012) . It has been linked to exacerbation of systemic autoimmunity (Miwa et al., 2012) and increased focal cerebral ischemia (Harhausen et al., 2010) . In the eye, Cd59a À/À mice developed choroidal neovascularization (CNV) earlier after laser injury and showed increased membrane-attack complex deposition (Bora et al., 2007) . Furthermore, a soluble CD59 has been shown to attenuate CNV in the laser-induced CNV mouse model (Cashman et al., 2011) . Cd59a À/À mice have also been described as having spontaneous intravascular hemolysis and hemoglobinuria (Holt et al., 2001 ), but overall, their phenotype is considered rather mild and modifying of other diseases that have an inflammatory component. In this study, we aim to understand the role of the Cd59a complement regulator for the maintenance of the ocular-immune homeostasis during aging and how dysregulation of the complement system by its genetic ablation may contribute to ocular pathology with age. We found that, Cd59a deficiency leads to an increased age-related accumulation of microglia and/or macrophages in the subretinal space and to a preferential dysregulation of the complement system in the RPE-choroid compared with the neuroretina indicating a shift in innate immune homeostasis with age. However, alone or in combinations with moderate light exposure as an additional trigger, Cd59a deficiency was not sufficient to cause vascular changes in the choroid or retinal degeneration and dysfunction. Nevertheless, this data emphasizes the preferential susceptibility of the RPE-choroidal complex to molecular consequences induced by aging and the dysregulation of the alternative complement pathway.
Material and methods

Animal procedures
We used Cd59a knockout (Cd59a À/À ) mice which were kindly provided by Professor Paul Morgan from Cardiff University where they were produced and backcrossed over >8 generations on a C57BL/6J background (Holt et al., 2001) . We backcrossed the homozygous line to C57BL/6J (Harlan UK Ltd, Blackthorn, UK) mice over 1 additional generation to generate a heterozygote stock that was used to generate Cd59a À/À and wild-type (WT) littermate controls. All mice were genotyped for Cd59a and all breeding pairs were further confirmed as rd8 (Crb1
) mutation free (Luhmann et al., 2012) . All animals were kept in the same animal room and 12-hour light-dark cycles [33 AE 28 lux inside the cage (Luhmann et al., 2013) ] with food and water available ad libitum. For light exposure experiments, mice were moved into a fully ventilated light exposure rack (in house construction). Illumination was controlled by integrated light meters at animal level within the cage. The mice had food and water available ad libitum. For in vivo procedures, mice were anesthetized by a single intraperitoneal injection of 0.2 mL of a mixture of medetomidine hydrochloride (1 mg/mL), ketamine (100 mg/mL), and sterile water in the ratio of 5:3:42 (Orion pharmaceuticals, Helsinki, Finland). Post-procedure anesthesia was reversed by an injection of 0.2 mL of ANTISEDAN (Pfizer pharmaceuticals, USA). Whenever required the pupils were dilated using 1% tropicamide (Chauvin Pharmaceuticals, Romford, UK). All procedures were performed under the approval of local and national ethical and legal authorities and in accordance with the Association for Research in Vision and Ophthalmology statements on the care and use of animals in ophthalmic research. The study was approved and covered by the UK Home Office (PPL 70/1279).
In vivo imaging and quantification of fluorescent spots
As previously described (Charbel Issa et al., 2012) , autofluorescence imaging was performed using the HRA2 confocal scanning laser ophthalmoscope (cSLO; Heidelberg engineering, Germany). After full dilation of the pupils, the cornea was kept moist using ophthalmic lubricant. The 55 angle lens was used for images acquisition and all images were acquired using the highresolution mode and automated real-time mode. The near-infrared reflectance mode (820 nm laser) was used for alignment of the image centrally at the optic nerve head. After focusing at the retinal vasculature and/or nerve fiber layer (inner retina) the cSLO was switched to fundus autofluorescence (FAF) mode (excitation 488 nm, emission 500e700 nm). For recordings of the outer retina, the focus was adjusted.
The images were analyzed by 2 independent masked graders, counting the fluorescent spots per image. To assess intergrader reliability, Bland-Altman analysis was performed.
Flat mounts, sections, and immunohistochemistry
Flat mounts and retinal cryosections were prepared as described before (Luhmann et al., 2012) . In brief, eyes for RPE-choroidal flat mounts were fixed at room temperature for 10 minutes in 4% paraformaldehyde (PFA) before dissection and postfixed again in 4% PFA and/or phosphate-buffered saline (PBS) for a total of 1 hour. Tissue for cryosectioning was fixed with 4% PFA for 1 hour and washed 3Â in PBS before it was embedded in optimal cutting temperature compound. Fifteen micrometerethick sections and flat mounts were blocked with PBS, 1% bovine serum albumin (Sigma-Aldrich, UK), and 5% nonspecific goat serum (AbD Serotec, UK) including 0.3% (cryosections) or 3% (flat mounts) Triton X-100 (Sigma Aldrich) for 1 hour. The samples were incubated overnight at 4 C with a mix of the respective antibodies including a 1:500 dilution of rabbit anti Iba1 antibody (#019e19741, WAKO, Japan), 1:300 rat anti-GFAP (#345860, Calbiochem), 1:200 biotinylated lectin-B4 (SigmaAldrich), 1:30 phalloidin staining, (Invitrogen, UK) in the respective blocking solution. After washing 4 times with PBS, the samples were incubated for 2 hours at room temperature with a 1:500 dilution of the respective AlexaFluor-conjugated secondary antibodies (Invitrogen-Molecular Probes, the Netherlands). The samples were washed 4 times with PBS, counterstained with 1:1000 DAPI (4 0 ,6-diamidino-2-phenylindole) (Invitrogen), and mounted with fluorescence mounting medium (Dako Fluorescence Mounting Medium, Dako, UK). Images were obtained using a confocal laser-scanning microscope (Leica DM5500Q, Leica Microsystems, Germany).
Characterization of choroidal microvasculature
Choroidal vasculature was visualized by adapting the protocol described in (Saint-Geniez et al., 2009) . Briefly, mice were transcardially perfused with 10-mL oxygenated Ringer's solution containing heparin (prewarmed to 37 C) at a rate of 2 mL/min. That was followed by 4-mL FITC-conjugated Griffonia simplicifolia isolectin B4 (0.1 mg/mL; Vector Laboratories) and 10-mL PBS, to remove nonspecific binding. Eyes were enucleated, cornea, anterior chamber, and retina removed and the RPE-choroidal tissue flat-mounted and incubated for 2 minutes in 0.25% trypsin (Life Technologies, UK). Gentle brushing and pipetting was applied on the tissue to remove the RPE cells and facilitate the visualization and analysis of choroidal vessels. Two photographs were taken per region of interest (center and periphery), and the area covered by vasculature per total area of the image was determined for quantification using ImageJ software.
Histology and quantification analysis of the outer nuclear layer
Eyes were enucleated and fixed for 24 hours in Serra's fixative (ethanol 96%:formaldehyde 37%:acetic acid 100% in a ratio of 6:3:1) and were embedded in paraffin after dehydration in 70% and 100% isopropanol. Sections were cut at 5 mm and stained with hematoxylin and eosin. Images were obtained from the central and the peripheral region of sections containing the optic nerve.
To quantify the nuclei of the outer nuclear layer (ONL), rows of photoreceptors were counted in 3 columns per image per eye and the mean number of photoreceptor rows AE standard deviation (SD) per section was calculated for each animal.
Electroretinogram
Electroretinograms (ERGs) were recorded from both eyes of 9-month-old Cd59a À/À mice and age-matched WT controls. All animals were dark-adapted overnight for 16 hours before ERG recordings. The animals were prepared for ERG recordings as described previously (Tan et al., 2009 ). ERGs were recorded using commercially available equipment (Espion E2, Diagnosys LLC, UK). Band-pass filter cutoff frequencies were 0.312 Hz for the low and 1000 Hz for the high frequency cutoff. Scotopic recordings were obtained from dark-adapted animals at the following increasing 
Quantitative reverse transcription polymerase chain reaction
After enucleation, mouse eyes were dissected under a microscope to obtain the neurosensory retina and RPE-choroid. Samples were immediately snap-frozen in liquid nitrogen and stored until further use at À80 C.
RNA was extracted with an RNeasy mini kit as per the manufacturer's instructions (RNeasy, Qiagen, UK). RNA yield was quantified on a spectrophotometer (Nanodrop 1000, Thermo Scientific, USA). Equal quantities of 300e400 ng RNA were used as a template for complementary DNA (cDNA) manufacture for each sample. cDNA was produced with a QuantiTect reverse transcriptase kit (Qiagen, UK).
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed to detect messenger RNA levels of mouse C3, Cfb, Cfd, and Properdin using a commercial thermal cycler (7900HT, Applied Biosciences, USA). All reagents were obtained from Roche Diagnostics (UK). The technique was based on FAM (fluorescein amidite)-labeled hydrolysis probes (Roche Diagnostics), and primers were designed for specific probe-binding regions using the Roche Universal Probe Library (Table 1 ). All reactions were performed in triplicate in 20-mL reactions. OO Ct values were calculated against 9-month-old WT samples (5 or 15 months, respectively when no 9 months data were generated). The assays were repeated with retinas and RPE-choroid from at least 5 animals for each group.
Statistical analysis and number of animals used
Statistical analyses were performed using GraphPad Prism 5 for Windows (GraphPad Software Inc, USA). The average variables of >2 groups were compared by analysis of variance (ANOVA) with Holm-Sidak for multiple comparisons. We have included a À/À mice show increased age-related autofluorescent fundus spots in vivo. Scanning laser ophthalmoscopy of the posterior pole of Cd59a À/À (DeF) and C57BL/6 mice (AeC). Fundus autofluorescence (FAF) images show abundant autofluorescent fundus spots in this extreme example of a Cd59a À/À mouse (F). Note the location and spread pattern of the spots in the outer retina and/or RPE interface (F), whereas the FAF signal from the inner retina (E) and the near-infrared image (IR) (D) are unremarkable. Quantification of autofluorescent spots (G) showed a significant increase of spots from 4 to 15 months in both, wild type (WT) and Cd59a À/À , groups reflecting a natural age-related process with high variation in the cohorts (*p < 0.05). However, there is a significant difference between the genotypes (mean number of spots AE standard deviation, 2-way analysis of variance with Holm-Sidak post hoc test, p 9months,
summary table that shows the number of animals used in the different experiments of this study (Table 2) .
Results
Increased age-related accumulation of autofluorescent spots in AF-SLO fundus images of Cd59 À/À mice
To detect fundus changes due to the absence of complement regulator Cd59a, we analyzed the FAF signal by cSLO. To focus on age-related changes, we imaged eyes of C57BL/6 WT mice (n ¼ 47, Fig. 1AeC ) and Cd59a knockout mice (n ¼ 62, Fig. 1DeF ) from 3 cohorts of different age (4, 9, and 15 months). The most prominent feature observed were autofluorescent spots of the posterior pole ( Fig. 1 F) , located at the outer retina and/or RPE interface. Near-infrared images and the FAF signal of the inner retina did not show any abnormalities in WT and Cd59a knockout mice ( Fig. 1 A  and D) . These spots were also observed in C57/BL6 mice and increased with age. To quantify these changes the number of spots per image were analyzed by 2 independent masked graders. To assess intergrader reliability Bland-Altman analysis was performed showing a high reliability between the graders (Bias, À3.38; SD, 13.1). Quantification of autofluorescent spots (Fig. 1G) showed a significant increase of spots from 4 to 15 months in both WT and Cd59a À/À groups reflecting a natural aging process with high variation in the cohorts. However, the age-related accumulation of these spots is significantly increased in Cd59a À/À mice with age (mean number of spots AE SD, 2-way ANOVA with Holm-Sidak post hoc test, p 9months, 15months < 0.008) suggesting that loss of the complement regulator Cd59a contributes to an increase of this fundus feature with age.
3.2. Subretinal macrophages and/or microglia are the cellular correlate of autofluorescent spots in AF-SLO fundus images
Autofluorescent spots in the fundus of mice are a common and well described feature that has been linked to an accumulation of lipofuscin loaded macrophage and/or microglia in the subretinal space (Luhmann et al., 2009) . To confirm the nature of the autofluorescent spots in Cd59a À/À mice, immunohistochemistry for the myeloid cell marker Iba1 was performed on RPE-choroidal flat mounts and retinal cryosections (Fig. 2AeD) . We identified an Iba1-positive subretinal cell population that included cells with amoeboid and ramified morphology supporting these cells to be subretinal macrophages and/or microglia. Their localization on the apical surface of the RPE on the RPE and/or choroidal flat mount ( Fig. 2A and B ) and in retinal sections ( Fig. 2C and D ) of WT and Cd59a-deficient mice, respectively correlated well with the spread pattern, size, and location of the autofluorescent spots observed in vivo in the autofluorescence scanning laser ophthalmoscopy (AF-SLO) fundus images of Cd59a À/À mice and thereby confirming the subretinal macrophages and/or microglia to be the cellular correlate of these autofluorescent spots.
3.3. Cd59a deficient and WT mice show similar retinal structure and function during aging
To assess whether the Cd59a deficiency leads to structural changes in retinal morphology, we prepared 5-mm paraffin sections and stained with hematoxylin and eosin (Fig 3A) . A qualitative analysis did not reveal significant changes at 4 or 15 months. To quantify changes of the ONL we analyzed ONL thickness by quantification of nuclei per column (Fig. 3B ) in 4-and 15-month-old animals (average of 3 counts per eye; n [WT] ¼ 6, n [Cd59a
. This did not show a significant difference between genotype and age. To assess changes in retinal functions, we performed scotopic and photopic ERG at 4 (data not shown) and 9 months (Fig. 3C ). This did not reveal any significant abnormalities in b-wave amplitude of Cd59a À/À mice compared with To analyze whether deficiency of Cd59a may lead to age-related changes in the choriocapillaris, the microvasculature closest to the basal side of the RPE and the accumulating macrophages and/or microglia, we performed perfusions with FITC-conjugated isolectin B4 and trypsin digests of RPE and/or choroidal flatmounts on 9-to 10-month-old Cd59a À/À and age-matched WT littermate controls (Fig. 4AeC) . The qualitative analysis of FITC-labeled choriocapillaris did not reveal significant changes in its morphology (Fig. 4A vs. B) . In addition, the quantification of the percentage area covered by this microvasculature relative to the total image area in the central and the periphery of the RPE-choroidal flat mount did not show significant differences. This suggests that in the absence of Cd59a also the morphology of the choriocapillaris is well maintained with age, at least up to 9e10 months of age (Fig. 4AeC, n [WT] ¼ 4, n [Cd59a To analyze the effects of complement regulator Cd59a deficiency on the local expression of main factors of the alternative pathway, we performed qRT-PCR on ocular tissue samples from 4-, 9-, and 15-month-old WT and Cd59a À/À mice (number of mice per age and genotype ¼ 5e6). The eyes were dissected into neuroretina and RPE-choroid complex, allowing separate analysis of these 2 compartments. We performed qRT-PCR for expression of complement component 3 (C3), complement factor B (Cfb), Cfd, and Properdin. In the RPE-choroid samples (Fig. 5 ), we observed a significant age-related increase in all analyzed complement genes in WT and Cd59a À/À mice. For C3, Cfb, and Cfd, but not Properdin, this increase was significantly more pronounced in the Cd59a À/À mice (2-way ANOVA). C3 expression at 4 months was very low in both, WT and Cd59a À/À mice (WT: Cd59a À/À ratio 1:0.8) but increased about 29-fold in the WT by 9 months of age (Fig. 5) . The increase in local C3 expression from 4 to 9 months was even more pronounced in Cd59a À/À mice. By the age of 9 months, C3 expression in Cd59a p Cfd < 0.02). The local expression of Properdin had a different profile than the other examined genes. There is a significant increase of local Properdin expression from 4 and 9e15 months, but there is no difference between WT and Cd59a À/À mice (WT:Cd59a À/À ratio at 4 months 1:1.5; at 9 months 1:1.5; and at 15 months 1:0.9) (p Properdin < 0.002).
In the neuroretinal samples, overall the relative change in expression of complement genes with age were very small compared to that in the RPE choroid, as is immediately visible by the different scales of the axes in Figs. 5 and 6. However, we still detected significant changes with age in the retinal expression levels of Cfd and Properdin but not C3 and Cfb which nevertheless both showed a variable trend toward increased expression in Cd59a À/À mice at 15 months (WT:Cd59a À/À ratio at 15 months for C3 1:3.6 and for Cfb 1:2.3). Retinal Cfd levels were very low and could only be detected reliably at 15 months when there was a significant increase in Cd59a À/À mice (t test p < 0.04; WT:Cd59a À/À ratio 1:6.3). Properdin expression in the neuroretina increases with age from 9 to 15 months-by a factor of 12 in WT mice and a factor of 7 in the Cd59a À/À animals. Although the WT:Cd59a À/À ratio at 9 months was equivalent in both (1:1.1), the detected difference in the age-related increase resulted in a significant but small decrease of Properdin expression at 15 months in Cd59a À/À mice compared with WT animals (WT:Cd59a À/À ratio at 15 months 1:0.65). This observation did not follow the trend of the other genes (p Properdin < 0.0001) but should be interpreted with care because relative expression changes below 2-fold change may be at the limit of detection for a relative quantification RT-PCR method. Overall, these expression analyses revealed that the combination of age and Cd59a deficiency leads to a preferential expression increase of complement genes in the RPE-choroid, while the neuroretina shows rather minor expression changes in these genes.
Enhanced moderate light exposure for 7 days does not alter local expression of complement genes in Cd59a deficient mice on a C57Bl/6 background
To analyze the effects of the combination of Cd59a deficiency with moderate light exposure as an additional potential trigger for accelerated complement dysregulation, we exposed 5-month-old Cd59a À/À mice and age-matched littermate WT controls to 7 days constant 1000 lux white light and compared them to age-matched controls in normal housing conditions. In previous experiments, we have shown that this light exposure regime can induce the local activation of complement factor expression in Balb/c mice, (article in preparation). qRT-PCR of main components of the alternative complement pathway (Fig. 7) did not show significant changes in gene expression of C3, Cfb, Cfd, and Properdin after light exposure in either group of animals. (2-way ANOVA with Holm-Sidak post hoc test; n per group ¼ 5e6).
Discussion
Our data suggests that Cd59a contributes to a tight control of the immune homeostasis of the eye and that it is particularly important for the maintenance of the immune homeostasis of the RPEchoroidal complex during aging. This is indicated by the observation that Cd59a À/À mice show significantly increased accumulation of subretinal macrophages and/or microglia during their aging process compared with age-matched WT animals and further supported by the preferential increase of the expression of the complement activators C3, Cfb, and Cfd in the RPE-choroidal complex during aging that was further increased in Cd59a À/À mice.
Subretinal macrophages and/or microglia accumulation
suggests an innate immune activation in the eye of Cd59a À/À mice during aging
Accumulation of macrophage and/or microglia in the subretinal space has been described in WT mice as a typical feature of age-related processes and represents a normal parainflammatory response of the cellular innate immune system to age-related tissue changes to maintain retinal homeostasis (Luhmann et al., 2009; Xu et al., 2009) . The fact that Cd59a À/À mice show an increase in the accumulation of these cells and a far higher variability in this feature with age than WT mice supports that Cd59a plays a role in controlling the ocular innate immune homeostasis. However, also in WT mice the accumulation of the subretinal cells not only increases but also becomes more varied with age indicating that additional alterations in other immune regulatory pathways, such as, for example, the chemokine signaling pathways via Ccl2 or Cx3cl1 (Luhmann et al., 2009; Raoul et al., 2008) , may also be involved in the observed shift of immune homeostasis. However, there has been some controversy about the origin of these cells, with some investigators referring to them as subretinal macrophages, implying that they have moved into the subretinal space from the circulation, and some investigators referring to them as activated microglia, implying that these cells have migrated from the inner retina toward the RPE. Recent evidence suggests that both could be true and that these subretinal cells represent a mix of both myeloid cell populations (Sennlaub et al., 2013) , indicating an altered innate immune status in the retina of Cd59a À/À mice.
The RPE-choroid of Cd59a
À/À mice is particular vulnerable to complement dysregulation with age
The local expression of complement factors by the RPE and neurosensory retina has been well described in humans (Anderson et al., 2002) , mice Luo et al., 2011) , and in vitro cell culture Luo et al., 2011) . It is also known that there is an increase of local expression with age . In mouse, the complement regulator Cd59a is strongly expressed in the neurosensory retina and to a lesser extent the RPE. There also seems to be stronger expression in the mouse eye than in nonocular tissues (Faber et al., 2012; Yang et al., 2009 ) which highlights the relevance of Cd59a for the eye. It has also been described that the expression of Cd59a increases in the neuroretina with age, whereas À/À mice with age. Age-and genotype-related effects were generally more pronounced in the RPE and/or choroid complex showing significant age-related changes in all tested complement genes. C3, Cfb, and Cfd also showed significant changes between the genotype whereas Properdin showed a significant change with age, irrelevant of the genotype. (fold change to 9-month-old WT þ standard deviation, 2-way analysis of variance with HolmSidak post hoc test, p C3,Cfb < 0.0001, p Cfd < 0.02, p Properdin < 0.002, n per age and genotype ¼ 5e6, n.d.¼ not detectable or below threshold). Abbreviations: RPE, retinal pigment epithelium; qRT-PCR, quantitative reverse transcription polymerase chain reaction; WT, wild type.
it does not significantly alter in the RPE-choroid of WT mice (Faber et al., 2012) . In our study, however, the genetic ablation of the membrane-bound complement regulator Cd59a caused a preferential increase of C3, Cfb, and Cfd expression with age in the RPE-choroid of Cd59a À/À mice relative to that observed during aging in WT mice. In contrast, in the neuroretina, the overall relative expression changes were much smaller than those in the RPE-choroid and only a trend for increased C3 and Cfb expression with age and Cd59a À/À genotype was observed suggesting that in particular the RPE-choroidal complex, and only to a lower degree the retina, is affected by the localized complement dysregulation due to Cd59a deficiency during aging. Such a preferential change in expression of inflammatory genes in the RPE-choroidal complex with age is consistent with a previous microarray study in WT mice showing the preferential increase of many inflammatory genes in the RPE-choroid with age . In contrast to the 3 other activators for the alternative complement pathway, Properdin showed a significant age-related increase in both RPE-choroid and retina that was not prominently affected by the Cd59a deficiency suggesting that its expression may be independently regulated during aging. Our study design does not distinguish specific cell types that may be responsible for the observed upregulation of complement genes. Currently, there is no available immunohistochemistrybased marker that can distinguish the origin of macrophages and microglia cells. Both RPE and microglia and/or macrophages have been described as relevant sources of complement expression that increases with age (Luo et al., 2011) and might be both relevant in subretinal accumulation (Sennlaub et al., 2013) . However, the relative contribution may depend on the degree and nature of the inflammatory stimulus that leads to their activation. Macrophage and/or microglia might be important cellular sources of local complement expression in the eye (Ma et al., 2013) and among them in particular infiltrating subretinal macrophages have been shown to produce C3 after acute light exposure (Rutar et al., 2011) . The latter may be a major source of the observed increase in expression of C3, Cfb, and Cfd in the RPE-choroidal samples because the increase in expression of these factors seems to correspond to an increase in these cells in the fundus. However, we cannot exclude that resident myeloid cells in the RPE-choroid may also contribute significantly, similarly to retinal microglia, which have been shown to upregulate these complement factors with age (Ma et al., 2013) . Properdin may possibly be derived from neutrophils that have been suggested as a major source of this activator of the alternative complement pathway during innate immune responses (Camous et al., 2011) . In addition, the interplay of macrophages and/or microglia and RPE might be relevant. It has been shown that RPE-expression of complement factors can be regulated by different activation states of macrophages. In vitro experiments showed that RPE cells, after exposure to conditioned medium from macrophages of different activation states (M1, M2b), respond with an upregulation of complement factors, for instance with a 30-fold increase in Cfb and C3 expression (Luo et al., 2013) . These finding suggest that both resident and recruited myeloid cells and RPE cells may contribute to local activation of the alternative complement pathway, either by opsonization or other mediators that may further stimulate cellular components of the immune system and thereby generate an activation loop between the humoral and cellular innate immune system that may propel local changes.
Cd59a-mediated innate immune dysregulation is not sufficient to cause retinal degeneration
Despite clear evidence for an increasing overactivation of the innate immune system in the ocular tissues of Cd59a À/À mice, we have not found any significant histological or functional differences in the retina of young and aged Cd59a À/À mice compared with age-matched WT controls. Even at 15 months there was no significant difference in retinal histology or outer nuclear layer thickness suggesting that Cd59a deficiency alone is not sufficient to cause retinal degeneration or dysfunction with age. Furthermore, qualitative and quantitative analysis of the choriocapillaris did not show a significant difference in the Cd59a knockout mice. The preferential molecular changes in the RPE-choroid seem inconsistent with the reported higher expression level of Cd59a in the neurosensory retina and its increase with age (Faber et al., 2012) , but may be consistent with the idea that a major source of complement proteins is derived from the systemic circulation (Anderson et al., 2010) . Our observation may thus highlight the differences in the control of the immune status between the 2 ocular compartments, on one hand the neuroretina as a part of the central nervous system and on the other hand the RPE-choroid with its strong influences from the systemic circulation. Furthermore, the lack of manifestation of any obvious retinal pathology in this study may be in line with the general perception that Cd59a deficiency represents only one of many factors that may control the immune homeostasis in the aging retina and RPE-choroid. It could, for example, be that in the context of Cd59a deficiency in mice additional factors and triggers are required to induce enhanced retinal pathology that would manifest in RPE damage or photoreceptor loss with age. Such additional factors could be an altered expression of complement regulators during the course of AMD, an idea that was supported by recent studies on human AMD eyes (Ebrahimi et al., 2013) or by the observation that several risk conveying polymorphisms in complement genes for AMD influence the activation of the C3 convertase synergistically (Heurich et al., 2011) . However, the interspecies differences of the complement system in human and mice need to be considered. Mice have 2 homologue Cd59 genes. They also have additional cell bound regulators, most notably Crry, that could possibly compensate for Cd59a absence. Thus, it could, for example, be that in the context of Cd59a deficiency in mice, an additional loss of the murine homologue Cd59b (Donev et al., 2008) are required to induce enhanced retinal pathology that would manifest in RPE damage or photoreceptor loss with age. Enhanced local stress or additional triggers for innate immune activation, such as photo-oxidative protein adducts in the retina (Weismann et al., 2011) , may also increase local complement dysregulation and ocular pathology. However, moderately-enhanced constant light for 7 days in combination with Cd59a deficiency did not result in a significantly enhanced complement dysregulation in either of the 2 ocular compartments. This suggests that Cd59a deficiency, at least in the context of the C57Bl/6 genetic background, which is more resilient to light (Ng and Streilein, 2001) , is not sufficient to cause an enhanced local complement dysregulation in response to this light trigger, that in Balb/c mice initiates enhanced local complement activation and ocular pathology (unpublished observations, manuscript in preparation).
4.4. The potential role of altered complement regulator expression in the RPE-choroidal complex in the pathology of AMD
Overall, it is difficult to estimate the effects of local complement expression on age-related pathology such as AMD. The total locallyproduced amount of complement factor proteins might be quite irrelevant compared with the abundant amount derived from the plasma. However, the specific local increase in secretion of complement factors, for example, by recruited myeloid or local RPE cells, in proximity to complex barriers such as Bruch's membrane and the inner blood-retinal barrier may drive activation of the complement system and thereby local pathology. It may be that the relatively lower Cd59a RNA levels in the RPE-choroid together with the higher level of complement expression with age simply reflects the incapability of this "peripheral" tissue compartment to maintain immune homeostasis with age, whereas in the neuroretina in addition to the higher Cd59a expression also other immune suppressive mechanisms may be in place that maintain the immune homeostasis in the central nervous system. Recent evidence may support the idea that macrophages and microglia maybe the source of expression of C3 and CFB (Rutar et al., 2011) and thus it maybe that resident macrophages in the choroid can more actively respond to the age-related changes in the tissue, whereas their activation is suppressed in the retina.
Altered polarity of protein secretion pathways during aging might also be important in this respect, which is supported by the observation that Cfb secretion from the RPE occurs only apically in young mice but shifts toward a basal secretion in aged mice . Evidence for such local alterations in the expression of the complement regulator CD59 in AMD pathology in humans comes from a recent study that showed strong CD59 protein expression in the macular RPE and the subretinal space of early AMD patients compared with healthy subjects. In more advanced forms of AMD with altered RPE morphology, however, the CD59 expression was reduced (Ebrahimi et al., 2013) . It was therefore proposed that the initial upregulation of CD59 in response to early inflammation would be protective, while the later reduction in CD59 levels may be associated with disease pathology. Consistent with this idea, another in vitro experiment on primary human RPE cells showed an upregulation of expression of complement regulators, including CD59, in response to inflammatory cytokines (Yang et al., 2009) . Similarly, the reduction of local CFH expression in the choriocapillaris and Bruch's membrane of AMD donor eyes (Bhutto et al., 2011 ) also suggested that a reduction of local complement regulator expression might be associated with AMD pathogenesis. Our study, however, only in part supports this idea. Although we observed a preferential expression in local activators of the alternative complement pathway in the RPE-choroid as a consequence of the genetic ablation of the terminal complement pathway regulator Cd59a, we have not found any clear evidence for associated ocular pathology in these mice.
Our data, therefore, support a role of Cd59a in controlling the innate immune status of the RPE-choroidal complex and emphasizes the particular vulnerability of this ocular compartment to the dysregulation of alternative complement pathway during aging.
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